CF PharmTech, Inc., a Suzhou, China-based maker of inhalation products, raised US $50M in Series F financing.
This followed its US $90M Series E financing in January of 2020, in total, completing an equity investment deal of nearly US $140M within six months.
The investors participated in the Series F financing include BioTrack Capital, CICC Qichen, CICC Qide, SAIC Hengxu, GP M&A Fund and Watson Investment. Its existing investors including Passion Capital and Yuanming Capital also participated.
The company intends to use the funds to accelerate the commercialization of its inhalation products.
CF PharmTech is a fully integrated specialty pharmaceutical company dedicated to providing affordable and high-quality respiratory drugs globally. The company focuses on the development of drugs for the treatment of respiratory diseases in its facilities.